|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nifedipine#Warnings]] |
| {{Nifedipine}}
| |
| {{CMG}}; {{AE}}: {{AK}}
| |
| | |
| '''''For patient information about Nifedipine, click [[Nifedipine (patient information)|here]].'''''
| |
| | |
| ===PRECAUTIONS==
| |
| | |
| ===General===
| |
| | |
| ====Hypotension====
| |
| | |
| Because nifedipine decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of nifedipine is suggested. Close observation is especially recommended for patients already taking medications that are known to lower blood pressure. (See WARNINGS.)
| |
| | |
| ====Peripheral Edema====
| |
| | |
| Mild to moderate [[peripheral edema]] occurs in a dose dependent manner with an incidence ranging from approximately 10% to about 30% at the highest dose studied (180 mg). It is a localized phenomenon thought to be associated with vasodilation of dependent arterioles and small blood vessels and not due to left ventricular dysfunction or generalized fluid retention. With patients whose angina or hypertension is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.
| |
| | |
| ====Other====
| |
| | |
| As with any other non-deformable material, caution should be used when administering nifedipine extended-release in patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of nifedipine extended-release.
| |
| | |
| | |
| ===Laboratory Tests===
| |
| | |
| Rare, usually transient, but occasionally significant elevations of enzymes such as [[alkaline phosphatase]], [[CPK]], [[LDH]], [[SGOT]] and [[SGPT]] have been noted. The relationship to nifedipine therapy is uncertain in most cases, but probable in some. These laboratory abnormalities have rarely been associated with clinical symptoms; however, [[cholestasis]] with or without [[jaundice]]has been reported. A small (5.4%) increase in mean alkaline phosphatase was noted in patients treated with nifedipine extended-release. This was an isolated finding not associated with clinical symptoms and it rarely resulted in values which fell outside the normal range. Rare instances of allergic hepatitis have been reported. In controlled studies, nifedipine extended-release did not adversely affect serum uric acid, glucose, or cholesterol. Serum potassium was unchanged in patients receiving nifedipine extended-release in the absence of concomitant diuretic therapy, and slightly decreased in patients receiving concomitant diuretics.
| |
| | |
| Nifedipine, like other calcium channel blockers, decreases platelet aggregation in vitro. Limited clinical studies have demonstrated a moderate but statistically significant decrease in platelet aggregation and an increase in bleeding time in some nifedipine patients. This is thought to be a function of inhibition of calcium transport across the platelet membrane. No clinical significance for these findings has been demonstrated. | |
| | |
| Positive [[direct Coombs test ]]with/without [[hemolytic anemia]] has been reported but a causal relationship between nifedipine administration and positivity of this laboratory test, including hemolysis, could not be determined.
| |
| | |
| Although nifedipine has been used safely in patients with renal dysfunction and has been reported to exert a beneficial effect, in certain cases, rare, reversible elevations in [[BUN]] and serum [[creatinine]] have been reported in patients with pre-existing chronic renal insufficiency. The relationship to nifedipine therapy is uncertain in most cases but probable in some.
| |
| | |
| | |
| ===Carcinogenesis, Mutagenesis, Impairment of Fertility===
| |
| | |
| Nifedipine was administered orally to rats for two years and was not shown to be [[carcinogenic]]. When given to rats prior to mating, nifedipine caused reduced fertility at a dose approximately 30 times the maximum recommended human dose. There is a literature report of reversible reduction in the ability of human sperm obtained from a limited number of infertile men taking recommended doses of nifedipine to bind to and fertilize an ovum in vitro. In vivo mutagenicity studies were negative.
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03be089c-07e5-4f94-bfcc-c6101b311785
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |